AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06246916
Drug: relatlimab+nivolumab
RxNorm normalized name: nivolumab / relatlimab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV administration every 4 weeks (Q4W)
Trial: NCT04666129
Drug: Relugolix
RxNorm normalized name: Relugolix
DrugBank: Relugolix (DB11853)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: (Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day.~(Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day.
Trial: NCT04666129
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone acetate (1000 mg \[2 x 500-mg tablets\]) or fine-particle abiraterone acetate (500 mg \[4 x 125-mg tablets\]) will be administered orally once daily.
Trial: NCT04666129
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily.~(Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required.
Trial: NCT04666129
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For participants with mCRPC taking fine-particle abiraterone acetate, methylprednisolone 4 mg will be administered orally twice daily.
Trial: NCT04666129
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apalutamide 240 mg (4 x 60-mg tablets) will be administered orally once daily.
Trial: NCT04666129
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 dose will be administered every 3 weeks as a 1-hour intravenous infusion.
Trial: NCT05439772
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will take one dissolvable tablet of ondansetron prior to initiating PEG consumption.
Trial: NCT05760261
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam will be administered.
Trial: NCT06310200
Drug: Lidocaine Topical 4% Topical Solution
RxNorm normalized name: lidocaine topical 4% topical solution
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration
Trial: NCT04905407
Drug: Tamibarotene
RxNorm normalized name: Tamibarotene
DrugBank: Tamibarotene (DB04942)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Tamibarotene tablets will be administered per dose and schedule specified in the arm.
Trial: NCT04905407
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax tablets will be administered per dose and schedule specified in the arm.
Trial: NCT04905407
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine injection will be administered per dose and schedule specified in the arm.
Trial: NCT06208462
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200mg，i.v. , q3w
Trial: NCT06208462
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8mg,qd
Trial: NCT06208462
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg/m2，q3w
Trial: NCT06208462
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m2，q3w
Trial: NCT05104723
Drug: XELJANZ (tofacitinib)
RxNorm normalized name: Xeljanz
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The XELJANZ 5-mg tablets or 11-mg XR tablets will taken orally twice daily or once daily, respectively, in this study.
Trial: NCT05728502
Drug: Vericiguat (Verquvo, BAY1021189)
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
Trial: NCT05197192
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab i.v. infusion:~Cycle 1 Day 1: Obinutuzumab 100 mg i.v.~Cycle 1 Day 1 (or 2): Obinutuzumab 900 mg i.v.~Cycle 1 Day 8: Obinutuzumab 1000 mg i.v.~Cycle 1 Day 15: Obinutuzumab 1000 mg i.v.~Cycles 2-6: Day 1: Obinutuzumab 1000 mg i.v.
Trial: NCT05197192
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax p.o.:~Cycle 1: Days 22-28: Venetoclax 20 mg (2 x 10 mg)~Cycle 2: Days 1-7: Venetoclax 50 mg (1 x 50 mg)~Cycle 2:Days 8-14: Venetoclax 100 mg (1 x 100 mg)~Cycle 2:Days: 15-21: Venetoclax 200 mg (2 x 100 mg)~Cycle 2:Days: 22-28: Venetoclax 400 mg (4 x 100 mg)~Cycles 3-12: Days 1-28: Venetoclax 400 mg (4 x 100 mg)
Trial: NCT05197192
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cycles 15-24: Days 1-28:~100 mg acalabrutinib twice daily p.o. approx. every 12 hrs (corresponding to a total daily dose of 200 mg).
Trial: NCT05926414
Drug: Enavogliflozin
RxNorm normalized name: Enavogliflozin
DrugBank: Enavogliflozin (DB18970)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treated with Envlo tab. 0.3mg
Trial: NCT05926414
Drug: Enavogliflozin
RxNorm normalized name: Enavogliflozin
DrugBank: Enavogliflozin (DB18970)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Envlomet SR Tablet 0.3/1,000mg
Trial: NCT05804591
Drug: Pregabalin 150mg
RxNorm normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose of pregabalin 150mg in a capsule per os 1 hour before start of the operation.
Trial: NCT05721989
Drug: Ziltivekimab B
RxNorm normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single s.c. injection of 15 mg ziltivekimab B (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
Trial: NCT05721989
Drug: Ziltivekimab D
RxNorm normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single s.c. injection of 15 mg ziltivekimab D (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
Trial: NCT05721989
Drug: Ziltivekimab C
RxNorm normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single s.c. injection of 15 mg ziltivekimab C (30 mg/mL) by single-use pre-filled syringe assembled into a shield-activated pen-injector on Day 1.
Trial: NCT04743934
Drug: Flibanserin 100 MG
RxNorm normalized name: flibanserin 100 MG
DrugBank: Flibanserin (DB04908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flibanserin 100mg tablets taken by mouth daily at bedtime
Trial: NCT06778824
Drug: Takepron
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants are expected to take a proton-pump inhibitor (PPI) for 12 weeks, with a dosage of 30 mg taken once a day.
Trial: NCT06778824
Drug: Zoloft 50Mg Tablet
RxNorm normalized name: Zoloft 50mg Tablet
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants are expected to take a selective serotonin reuptake inhibitor (SSRI) for 12 weeks, with a dosage of 50 mg taken once a day.
Trial: NCT06778824
Drug: Imipramine Pill
RxNorm normalized name: imipramine Pill
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants are expected to take tricyclic antidepressants (TCA) for 12 weeks, with a dosage of 25 mg taken twice a day.
Trial: NCT04997382
Drug: Chemotherapy alone or Chemotherapy plus Immune Checkpoint Inhibitors with or without Bevacizumab
RxNorm normalized name: Medicated Pad or Tape
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immune Checkpoint Inhibitors, for pembrolizumab, 200mg ivgtt once,every 21 days; for Atezolizumab, 1200mg vgtt once,every 21 days.
Trial: NCT04997382
Drug: Chemotherapy alone or Chemotherapy with or without Bevacizumab
RxNorm normalized name: Medicated Pad or Tape
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab, 15mg/kg，every 21 day
Trial: NCT06029257
Drug: Tildrakizumab
RxNorm normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As provided in real-world clinical practice.
Trial: NCT05723835
Drug: Somapacitan
RxNorm normalized name: Somapacitan
DrugBank: Somapacitan (DB15093)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Somapacitan 0.24 milligrams per kilograms per week (mg/kg/week) will be administered subcutaneously (s.c.) using PDS290 pen-injector.
Trial: NCT05675449
Drug: Elranatamab
RxNorm normalized name: ELRANATAMAB
DrugBank: Elranatamab (DB15395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCMA-CD3 bispecific antibody
Trial: NCT05675449
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: proteasome inhibitor
Trial: NCT05675449
Drug: Maplirpacept
RxNorm normalized name: Maplirpacept
DrugBank: Maplirpacept (DB18441)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD47-SIRP alpha-directed
Trial: NCT05286554
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: vaginal suppositories (400 mg twice daily) starting on the day after oocyte retrieval and will be continued till pregnancy assessed by serum β-HCG 15 days after ICSI, and if pregnant, for 10 weeks of gestation.
Trial: NCT05161715
Drug: Obicetrapib
RxNorm normalized name: Obicetrapib
DrugBank: Obicetrapib (DB14890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg obicetrapib
Trial: NCT06143566
Drug: Polypill
RxNorm normalized name: POLYPILUS FRONDOSUS WHOLE
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A combination of finerenone 10 mg, empagliflozin 12.5 mg, and losartan 50 mg or 100 mg within a polycapsule.
Trial: NCT06166992
Drug: BI 1291583
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1291583
Trial: NCT05992883
Drug: Triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention will be an injection containing 0.5 mL of triamcinolone 40 mg/mL (20 mg total of triamcinolone).
Trial: NCT05322707
Drug: Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhalation aerosol, 2 actuations orally inhaled twice daily
Trial: NCT05253833
Drug: Allopurinol Tablet
RxNorm normalized name: Allopurinol Tablets
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solid tablet
Trial: NCT06520514
Drug: Spesolimab
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spesolimab
Trial: NCT05763043
Drug: Ferric derisomaltose
RxNorm normalized name: ferric derisomaltose
DrugBank: Ferric derisomaltose (DB15617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants between the gestational ages of 14 to 42 weeks with iron deficiency will receive IV Ferric derisomaltose at a routine prenatal visit.
Trial: NCT06226129
Drug: Gadopiclenol
RxNorm normalized name: Gadopiclenol
DrugBank: Gadopiclenol (DB17084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadopiclenol for contrast enhanced MRI
Trial: NCT04564898
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part 1 • Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days~Part 2~• Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days
Trial: NCT04913064
Drug: White Button Mushroom Extract
RxNorm normalized name: button mushroom extract
DrugBank: Cultivated mushroom (DB10544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06752317
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive intrathecal dexamethasone 8 mg in 3 ml volume.
Trial: NCT06752317
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive intrathecal dexmedetomidine 0.5 µg/kg in 3 ml volume.
Trial: NCT06386770
Drug: Dexmedetomidine Injection [Precedex]
RxNorm normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group ΙI (group DL): erector spinae block will receive 30 ml (28 ml bupivacaine 0.25% plus dexamedetomedine (0.5µg/kg) diluted in 2ml normal saline Na cl 0,9% ) + 10ml IV normal saline will be injected over 10 min after 10 min from the induction of general anesthesia
Trial: NCT06386770
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: .Group Ι Block only (group BO) (control group): erector spinae block will receive 30 ml ( 28 ml bupivacaine 0.25% +2ml normal saline Na cl 0,9 %) +10ml IV normal saline will be injected over 10 min after 10 min from the induction of general anesthesia
Trial: NCT06386770
Drug: Dexmedetomidine in 0.9 % NaCl 200 Mcg/50 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
RxNorm normalized name: dexmedetomidine in 0.9 % NaCl 200 mcg/50 mL (4 mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group III (group D IV): erector spinea block will receive 30 ml ( 28 ml bupivacaine 0.25% +2ml normal saline Na cl 0,9%) + dexamedetomedine (0.5µg/kg) diluted with 10 ml normal saline IV infusion by syringe pump over 10 min after 10 min from the induction of general anesthesia.
Trial: NCT04081714
Drug: CNM-Au8
RxNorm normalized name: CNM-Au8
DrugBank: CNM-Au8 (DB17952)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids). Highly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to 0.5 mg/L (500 ppm). CNM-Au8 will be administered orally in volumes of 60 mL from single-dose HDPE containers. Participants will orally receive 30 mg of CNM-Au8 once daily.
Trial: NCT05947955
Drug: Rhu-pGSN
RxNorm normalized name: Rhu-pGSN
DrugBank: Recombinant human plasma gelsolin (DB15746)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration based on actual body weight
Trial: NCT06528444
Drug: Grup 2 dexametasona
RxNorm normalized name: Dexametasona
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexamethasone 1 capsule (6 mg)/day for 7 days
Trial: NCT05215067
Drug: AK104
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion,Specified dose on specified days
Trial: NCT05215067
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion,Specified dose on specified days
Trial: NCT05090124
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab 40mg, will be administered as a subcutaneous injection once fortnightly on four occasions. The actual Adalimumab product selected at site will be dictated by what is used in standard care.
Trial: NCT04923542
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Abemaciclib is an orally administered selective small-molecule inhibitor of CDK4 and CDK6 that is 14 times more potent against CDK4 than CDK6 in enzymatic assays that is approved for the treatment of advanced or metastatic breast cancers. Abemaciclib will be administered at a dose of 150 mg twice daily.
Trial: NCT06793748
Drug: TISSEEL Fibrin Sealant KIT
RxNorm normalized name: TISSEEL Fibrin Sealant KIT
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin Sealant (TISSEEL® VH SD Kit)
Trial: NCT05386043
Drug: FET F-18
RxNorm normalized name: FET F-18
DrugBank: FET F-18 (DB15405)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET scan with FET prior to biopsy
Trial: NCT05386043
Drug: O-15 Radioisotope
RxNorm normalized name: water, O-15
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET scan with O-15 Water prior to biopsy
Trial: NCT04774237
Drug: Carbachol
RxNorm normalized name: Carbachol
DrugBank: Carbamoylcholine (DB00411)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single drop in each eye at a visit.
Trial: NCT06484985
Drug: AXT-1003
RxNorm normalized name: Axtle
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
Trial: NCT04514497
Drug: Elimusertib
RxNorm normalized name: Elimusertib
DrugBank: Elimusertib (DB19041)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04514497
Drug: Irinotecan Hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04514497
Drug: Topotecan Hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05327686
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05327686
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05327686
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06250205
Drug: Obicetrapib
RxNorm normalized name: Obicetrapib
DrugBank: Obicetrapib (DB14890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT05086744
Drug: Iptacopan
RxNorm normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iptacopan 200 mg BID given orally (capsule)
Trial: NCT05133297
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tablets administered at 5 mg BID daily for 24 weeks.
Trial: NCT04756427
Drug: Sodium Citrate 4% Inj Syringe 3Ml
RxNorm normalized name: SODIUM CITRATE 4% INJ SYRINGE 3ML
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 ml of sodium citrate 4% locking solution instilled into the central catheter daily during the period that parenteral nutrition is not infusing, and will be withdrawn and disposed of prior to resuming infusion of parenteral nutrition
Trial: NCT04836429
Drug: Porfimer Sodium
RxNorm normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04684108
Drug: SG301
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase 1a will use an accelerated titration and 3+3 design with 9 dose cohorts: 0.005 mg/kg, 0.05 mg/kg,0.5 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg and 16 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 3 cohorts.
Trial: NCT05743621
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 160 mg daily PO
Trial: NCT06792344
Drug: anti-CD19 CAR-T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-targeting CAR-T cells
Trial: NCT05554939
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
Trial: NCT06087614
Drug: Cisplatin injection
RxNorm normalized name: cisplatin Injection
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy, weekly Inj Cisplatin 40mg/m2. This will be given if clinically indicated
Trial: NCT05809908
Drug: Tricaprilin
RxNorm normalized name: TRICAPRILIN
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each dose of IMP will be administered orally 30 minutes after completing a meal.~There is 1 g of tricaprilin per 2 ml of AC-OLE-01-VA.~Subjects will titrate from 5 g twice a day to 20 g twice a day, 40 g total daily dose of tricaprilin; 80 ml total daily dose of AC-OLE-01-VA, over the course of 3 weeks.
Trial: NCT04760613
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 mg oral daily use (each capsule of active drug contains 50 mg of CBD)